Cagrilintide/semaglutide
REDEFINE 6
Novo Nordisk · Phase 3 · Completed · Enrollment 300
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| CagriSema | Obesity or overweight | n/r | 44 | n/r | n/r |
| Semaglutide | Obesity or overweight | n/r | 44 | n/r | n/r |
| Placebo | Obesity or overweight | n/r | 44 | n/r | n/r |